Aardvark Therapeutics Q2 EPS Beats Estimate
Aardvark Therapeutics reports Q2 EPS of $(0.66), beating the $(0.91) estimate
Aardvark Therapeutics (NASDAQ: AARD ) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent.
This is unchanged from the same period last year.